Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Boosted by Graham Capital Management L.P.

Graham Capital Management L.P. increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 148.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,232 shares of the company’s stock after purchasing an additional 45,542 shares during the quarter. Graham Capital Management L.P.’s holdings in Teva Pharmaceutical Industries were worth $1,680,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of TEVA. FMR LLC increased its stake in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares in the last quarter. Duquesne Family Office LLC increased its stake in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock worth $198,303,000 after purchasing an additional 7,569,450 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC purchased a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $58,243,000. Finally, Marshall Wace LLP increased its stake in Teva Pharmaceutical Industries by 87.8% in the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company’s stock worth $113,625,000 after purchasing an additional 2,410,420 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

TEVA has been the topic of several research analyst reports. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, April 23rd. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Finally, Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus price target of $23.71.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $16.94 on Monday. The business’s 50-day moving average is $15.18 and its 200-day moving average is $17.44. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a market capitalization of $19.21 billion, a price-to-earnings ratio of -11.68, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The firm had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.